P2T designs so called phase 2 studies to answer a simple question: the ‘Null Hypothesis”. The null hypothesis can be confirmed or rejected on the basis of previously defined objective endpoints. For example: a new treatment, that generates in at least 1 out of 3 patients a measurable improvement and has no or only rarely serious side effects will be used in future clinical studies.
New treatments with too many side effects and with insufficient improvement in patients- that is less than 1 out of three patients, will be excluded from further studies, but will be published in the open medical literature.
We invite academic clinical-medical investigators to collaborate with us in P2T projects. Two principal investigators will lead each project: one employee of the academic institute and one P2T member.
If you are interested in participating in a P2T project, please contact us.